|
Antibiotics to Reduce Chorioamnionitis-Related Perinatal HIV Transmission Clinical Trials Data presented on Clinical Trials Search isn't meant to be a substitute for qualified health advice, calls or treatment using a genuine doctor. We are not docs. Always consult your dr. on Antibiotics to Reduce Chorioamnionitis-Related Perinatal HIV Transmission conditions. Clinical Trials Search.org is a site dedicated to listing clinical research studies in human subjects. Antibiotics to Reduce Chorioamnionitis-Related Perinatal HIV Transmission Clinical research trials and Antibiotics to Reduce Chorioamnionitis-Related Perinatal HIV Transmission healthcare trials occur in a lot of of places throughout the United States. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally assess the potency of new drugs. The intent of the studies / undertakings is to figure out certain human medical questions. Clinical trials are a popular means for mDs, government agencies, and private sector corporations to locate remedies for all kinds of circumstances, including Antibiotics to Reduce Chorioamnionitis-Related Perinatal HIV Transmission. Antibiotics to Reduce Chorioamnionitis-Related Perinatal HIV Transmission Clinical Trials and other clinical trials allow volunteers to obtain health treatment alternatives before they are available to the masses. Many times the participants undergo treatment for free, and sometimes they are paid for their time. Occasionally there is a cost for a Antibiotics to Reduce Chorioamnionitis-Related Perinatal HIV Transmission clinical trial. Participants typically obtain the most effective healthcare available for their Antibiotics to Reduce Chorioamnionitis-Related Perinatal HIV Transmission condition. Dangers are a reality, nonetheless, and can include extra or frequent mD trips, medical hazards (potentially life-endangering), and/or the treatment being uneffective. Trials are federally regulated with rigid guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "A" Clinical Trials Conditions > Antibiotics to Reduce Chorioamnionitis-Related Perinatal HIV Transmission  Antibiotics to Reduce Chorioamnionitis-Related Perinatal HIV Transmission
Antibiotics to Reduce Chorioamnionitis-Related Perinatal HIV Transmission
For Condition: HIV Infections
Status: No longer recruiting
Sponsor(s): National Institute of Child Health and Human Development (NICHD) , National Institute of Allergy and Infectious Diseases (NIAID),National Institute of Mental Health (NIMH),National Institute on Drug Abuse (NIDA)
Synopsis: The purpose of this study is to see if antibiotic drugs given to treat an infection of the uterus during pregnancy can reduce the chances of HIV being passed from an HIV-positive mother to her baby. A link between bacterial disease of the vagina, premature birth, infection of the uterus during pregnancy, and the passing of HIV from a mother to her baby has been found. Early treatment of these problems may reduce the risk of passing HIV from an HIV-positive mother to her baby. [Note: As of 02/21/03, enrollment into this study was halted because preliminary data showed that the study antibiotics were not effective in preventing mother-to-child HIV transmission.]
Details: Obstetric risk factors for HIV maternal-child transmission (MCT) include preterm birth, prolonged rupture of the membranes, and chorioamnionitis. Many preterm births are associated with and likely caused by chorioamnionitis. The relationship between bacterial vaginosis, preterm birth, histologic chorioamnionitis, and perinatal transmission of HIV has been consistently demonstrated. Perinatal HIV transmission is more common in preterm infants, and there is now evidence that subclinical chorioamnionitis is a substantial risk factor for MCT. For this study, the primary hypothesis is that early and appropriate treatment of subclinical chorioamnionitis prior to the onset of spontaneous preterm labor, and/or antibiotic treatment during labor, to prevent premature rupture of membrane-associated-chorioamnionitis, will reduce the risk of perinatal HIV transmission. [Note: As of 02/21/03, enrollment into this study was halted because preliminary data showed that the study antibiotics were not effective in preventing mother-to-child HIV transmission.] At 20 to 24 weeks, women who are randomized to receive antibiotics receive metronidazole and erythromycin for 7 days. Women randomized to the control group receive identically appearing placebos. With the onset of contractions and/or premature rupture of membranes, study participants will initiate a second oral course of antibiotics consisting of metronidazole and ampicillin or placebo every 4 hours, continuing after delivery until the course is completed. All HIV-infected women and their neonates will be offered the HIVNET 012 nevirapine (NVP) regimen. If the mother accepts the NVP for herself and her baby, she will be given 1 dose of NVP to be taken at onset of labor, and her baby will receive 1 dose of NVP at 72 hours post-birth or discharge, whichever occurs earlier. If the mother refuses NVP or is uninfected, she will receive a matched placebo at the 26- to 30-week visit to preserve participant confidentiality. This study takes place in Blantyre and Lilongwe, Malawi, in Lusaka, Zambia, and in Dar es Salaam, Tanzania.
Eligibility:
Study Type: Interventional, Prevention, Double-Blind, Efficacy Study
Minimum Age/Maximum Age: /
Genders: Female
Protocol Entry Criteria: Inclusion Criteria - HIV positive. - 20 to 24 weeks pregnant. - Willing to take the planned antibiotic treatment. - Planning to deliver at 1 of the study sites. - Willing to come back for follow-up visits for 1 year after the baby is born. Exclusion Criteria - Have taken antibiotics, except for syphilis or gonorrhea, within the last 2 weeks. - Are allergic to penicillin, ampicillin, erythromycin, or metronidazole. - Have major illnesses, such as diabetes, severe kidney or heart disease, or active tuberculosis, which might affect the pregnancy. - Are having major problems with the pregnancy, such as placenta previa, ruptured membranes, or multiple pregnancy. - Have a central nervous system disease, such as seizures. - Are taking anticoagulant drugs.
Total Enrollment: 3720
Location and Contact Information:
Overall Study Official:
TahaTaha, Study Chair, Johns Hopkins University
Megan Valentine
Research Triangle Park, North Carolina, 27709
United States
Additional Information:
Study ID Numbers: HIVNET 024;
Study Start Date:
Record last reviewed: March 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00021671
Other Hiv Infections Studies:
1. A Phase I Study of Safety and Pharmacokinetics of Nevirapine in HIV-1 Infected Pregnant Women and Neonates Born to HIV-1 Infected Mothers
2. A Study of Acyclovir to Help Prevent HIV Infection in People With Genital Herpes
3. A Comparative Study of a Combination of Zidovudine, Didanosine, and Double-Blinded Nevirapine Versus a Combination of Zidovudine and Didanosine
4. A Pilot Study To Evaluate the Effect of Retrovir (Zidovudine: AZT) in the Treatment of Human Immunodeficiency Virus (HIV) Associated Dementia and Neuromuscular Diseases
5. The Effect of Fish Oil Plus Fenofibrate on Triglyceride Levels in People Taking Highly Active Antiretroviral Therapy (HAART)
Related Studies:
Other HIV Infections Clinical Trials
Other North Carolina Clinical Trials
Other Research Triangle Park Clinical Trials
Antibiotics to Reduce Chorioamnionitis-Related Perinatal HIV Transmission
|
|
|
|
|
|
|
|
